Esophageal Cancer
Editor:Jie He, MD, PhD; Wayne L. Hofstetter, MD; Guy D. Eslick, DrPH, PhD

Publisher: AME Publishing Company; 1st edition (2015)
ISBN-10: 988140276X
ISBN-13: 978-9881402769
Hardcover: 296 pages
Language: English
Available at:
Esophageal cancer is one of those cancers you never really hear much about in the media. It is an infrequent cancer and unfortunately, it is a cancer that receives very little attention through the media or via national or international funding agencies. Many people are surprised to learn that you can even get cancer of the 'food pipe' and in general there is an enormous lack of education about the risk factors for this cancer in the community. Because esophageal cancer is increasing in the Western world there is an urgent need for substantial improvements in the early diagnosis, treatment and continued management of these patients. It is disturbing to note that over the last sixty years treatments have changed for esophageal cancer, but unfortunately the patient outcomes remain abysmal with 85% to 90% of patients dying within five years. It is imperative that cancer organizations and funding agencies provide funding and resources that will in turn lead to cutting- edge developments in understanding esophageal cancer and decrease the incidence and improve the survival for patients with esophageal cancer. This first edition book on "Esophageal Cancer" which contains a diverse range of articles taken from AME journals and include authors with expertise in molecular biology, diagnosis and treatment, therapeutic endoscopy, surgery, radiotherapy and medical treatment, and prognosis. This book provides a practical collection of articles that will be useful for researchers and clinicians.
Table of Content
Molecular Biology
1 MicroRNAs and esophageal cancer
11 Current status of novel agents in advanced gastroesophageal adenocarcinoma
Overview of Diagnosis and Treatment
26 Esophageal cancer: staging system and guidelines for staging and treatment
35 State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment
52 Current management of esophageal cancer
64 Systemic treatment of gastric and esophageal adenocarcinoma in elderly patients
Therapeutic Endoscopy
68 T1 esophageal cancer, request an endoscopic mucosal resection (EMR) for in-depth review
72 Endoscopic options for early stage esophageal cancer
83 Peroral endoscopic myotomy for esophageal achalasia
92 Endoscopic submucosal dissection for superficial Barrett's esophageal cancer in the Japanese state and perspective
99 Endoscopic therapies for Barrett's neoplasia
110 Photodynamic therapy for esophageal cancer
114 Cell sheets engineering for esophageal regenerative medicine
Surgery
118 Mckeown esophagogastrectomy
121 Minimally invasive and robotic Ivor Lewis esophagectomy
129 Robotic assisted Ivor Lewis esophagectomy in the elderly patient
137 Salvage esophagectomy
146 Extent of lymph node dissection: common hepatic artery lymph node dissection can be omitted for esophageal squamous cell carcinoma
154 Jejunal graft conduits after esophagectomy
162 A video demonstration of the Li's anastomosis--the key part of the "non-tube no fasting" fast track progaram for resectable esophageal carcinoma
167 Cervical triangulating stapled anastomosis: technique and initial experience
172 Managing complications Ⅰ:leaks, strictures, emptying, reflux, chylothorax
181 Managing complications Ⅱ:conduit failure and conduit airway fistulas
Radiotherapy and Medical Treatment
189 Current strategies in chemoradiation for esophageal cancer
199 The role of induction therapy
204 Overall survival analysis of neoadjuvant chemoradiotheray and esophagectomy for esophageal cancer
210 Safety and efficacy of esophageal stents preceding or during neoadjuvant chemotherapy for esophageal cancer: a systematic review and meta-analysis
218 Increased risk of death due to heart disease after radiotherapy for esophageal cancer
226 Radiation therapy in the postoperative management of esophageal cancer
237 Concurrent chemoradiotherapy with protracted infusion of 5-fiuorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer
243 Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations
Prognosis and Prediction
252 A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer
260 Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy
266 HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis
277 Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis
287 Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet?
294 Skin metastases from esophagogastric junction cancer